OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:38 UTC. Every row links to its source record.

EED embryonic ectoderm development

ENSG00000074266 · protein coding · Open Targets profile

Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Also recognizes 'Lys-26' trimethylated histone H1 with the effect of inhibiting PRC2 complex methyltransferase activity on nucleosomal histone H3 'Lys-27', whereas H3 'Lys-27' recognition has the opposite effect, enabling the propagation of this repressive mark. The PRC2/EED- EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. {ECO:0000269|PubMed:10581039, ECO:0000269|PubMed:14532106, ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737, ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:20974918, ECO:0000269|PubMed:28229514, ECO:0000269|PubMed:9584199}.

In 14 of 15 cancers, the evidence for EED comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751melanomamelanomamelanoma: somatic 0.30breast carcinomabreast carcinomabreast carcinoma: somatic 0.30ovarian carcinomaovarian carcinomaacute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.30non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.30hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.30prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.30small cell lung carcinomasmall cell lung carcinomasmall cell lung carcinoma: somatic 0.30lung adenocarcinomalung adenocarcinomalung adenocarcinoma: somatic 0.30plasma cell myelomaplasma cell myelomaplasma cell myeloma: somatic 0.30prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.30osteosarcomaosteosarcomaosteosarcoma: somatic 0.30urinary bladder carcinomaurinary bladder carcinomaurinary bladder carcinoma: somatic 0.30T-cell acute lymphoblastic leukemiaT-cell acute lymphoblastic leukemiaT-cell acute lymphoblastic leukemia: somatic 0.30papillary renal cell carcinomapapillary renal cell carcinomapapillary renal cell carcinoma: somatic 0.30

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand, High-Quality Ligand, Med-Quality Pocket
PROTAC
Literature, Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.14743000268936157 (upper bound 0.25727999210357666). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of EED's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of EED's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.